Abstract
The increasing prevalence of obesity world-wide has an expected consequent increase in diabetes and cardiovascular disease. Less attention has been paid to the effect of obesity on dementia. This overview discusses methodological issues related to the epidemiologic study of obesity and dementia, reviews results of long-term prospective studies, and briefly considers possible mechanisms for an obesity-dementia association. At least six cohort studies of 18 to 32 years duration confirm that overweight middle-aged or older adults are at increased risk of dementia in later life. In many of these studies, the association persisted after adjusting for classical cardiovascular risk factors. A few epidemiologic studies (and more laboratory studies not reviewed here) suggest biomarkers such as C-reactive protein, interleukin 6, and leptin may explain part of the obesity-dementia connection. If any of these factors are in the causal pathway to dementia, their reversal or prevention by weight control would have huge public health importance.
Keywords: Obesity, dementia, biomarkers, prevention, prospective studies
Current Alzheimer Research
Title: An Introduction to Obesity and Dementia
Volume: 4 Issue: 2
Author(s): Elizabeth Barrett-Connor
Affiliation:
Keywords: Obesity, dementia, biomarkers, prevention, prospective studies
Abstract: The increasing prevalence of obesity world-wide has an expected consequent increase in diabetes and cardiovascular disease. Less attention has been paid to the effect of obesity on dementia. This overview discusses methodological issues related to the epidemiologic study of obesity and dementia, reviews results of long-term prospective studies, and briefly considers possible mechanisms for an obesity-dementia association. At least six cohort studies of 18 to 32 years duration confirm that overweight middle-aged or older adults are at increased risk of dementia in later life. In many of these studies, the association persisted after adjusting for classical cardiovascular risk factors. A few epidemiologic studies (and more laboratory studies not reviewed here) suggest biomarkers such as C-reactive protein, interleukin 6, and leptin may explain part of the obesity-dementia connection. If any of these factors are in the causal pathway to dementia, their reversal or prevention by weight control would have huge public health importance.
Export Options
About this article
Cite this article as:
Barrett-Connor Elizabeth, An Introduction to Obesity and Dementia, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362074
DOI https://dx.doi.org/10.2174/156720507780362074 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyphenols: Well Beyond The Antioxidant Capacity: Gallic Acid and Related Compounds as Neuroprotective Agents: You are What You Eat!
Current Pharmaceutical Biotechnology The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Patenting Penicillium Strains
Recent Patents on Biotechnology The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease
Current Pharmaceutical Design Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin
Current Drug Targets Ischemic and Oxidative Damage to the Hypothalamus May Be Responsible for Heat Stroke
Current Neuropharmacology Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices
Current Alzheimer Research Chronic Hypoxia Potentiates Age-Related Oxidative Imbalance in Brain Vessels and Synaptosomes
Current Neurovascular Research The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology New Pharmacological Approaches in Infants with Hypoxic-Ischemic Encephalopathy
Current Pharmaceutical Design The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Vitamin D Levels in Middle-Aged Patients with Obstructive Sleep Apnoea Syndrome
Current Vascular Pharmacology Haptoglobin Phenotype Correlates with the Extent of Cerebral Deep White Matter Lesions in Hypertensive Patients
Current Neurovascular Research Association Serum S100B Protein in Alzheimer’s Disease: A Case Control Study from South India
Current Alzheimer Research Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?
CNS & Neurological Disorders - Drug Targets Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Role of Estrogens on Some Cognition-Related Aspects
Current Topics in Medicinal Chemistry